Background Susceptibility to the pandemic coronavirus disease 2019 (COVID-19) has recently been associated with ABO blood groups in patients of different ethnicities. This study sought to understand the genetic association of this polymorphic system with risk of disease in Iraqi patients. Two outcomes of COVID-19, recovery and death, were also explored. ABO blood groups were determined in 300 hospitalized COVID-19 Iraqi patients (159 under therapy, 104 recovered, and 37 deceased) and 595 healthy blood donors. The detection kit for 2019 novel coronavirus (2019-nCoV) RNA (PCR-Fluorescence Probing) was used in the diagnosis of disease. Results Mean age was significantly increased in patients compared to controls (49.8 ± 11.7 vs. 28.9 ± 6.6 years; p < 0.001). A similar observation was made in recovered (42.1 ± 10.4 vs. 28.9 ± 6.6 years; p < 0.001) and deceased (53.6 ± 9.7 vs. 28.9 ± 6.6 years; p < 0.001) cases. The mean age was also significantly increased in deceased cases compared to recovered cases (53.6 ± 9.7 vs. 42.1 ± 10.4 years; p < 0.001). There were gender-dependent differences in COVID-19 prevalence. The percentage of COVID-19 was higher in males than in females (all cases: 59.7 vs. 40.3%; recovered cases: 55.8 vs. 44.2%). Such male-gender preponderance was more pronounced in deceased cases (67.6 vs. 32.4%). Logistic regression analysis revealed that groups AB and B + AB were significantly associated with increased risk to develop COVID-19 (OR = 3.10; 95% CI 1.59–6.05; pc = 0.007 and OR = 2.16; 95% CI 1.28–3.63; pc = 0.028, respectively). No ABO-associated risk was observed in recovered cases. On the contrary, groups A (OR = 14.60; 95% CI 2.85–74.88; pc = 0.007), AB (OR = 12.92; 95% CI 2.11–79.29; pc = 0.042), A + AB (OR = 14.67; 95% CI 2.98–72.33; pc = 0.007), and A + B + AB (OR = 9.67; 95% CI 2.02–46.24; pc = 0.035) were associated with increased risk of death in deceased cases. Conclusions The findings of this study suggest that group AB may be a susceptibility biomarker for COVID-19, while group A may be associated with increased risk of death.
Background A case-control study was performed to examine age, gender, and ABO blood groups in 1014 Iraqi hospitalized cases with Coronavirus disease 2019 (COVID-19) and 901 blood donors (control group). The infection was molecularly diagnosed by detecting coronavirus RNA in nasal swabs of patients. Results Mean age was significantly elevated in cases compared to controls (48.2 ± 13.8 vs. 29.9 ± 9.0 year; probability [p] < 0.001). Receiver operating characteristic analysis demonstrated the predictive significance of age in COVID-19 evolution (Area under curve = 0.858; 95% CI: 0.841 – 0.875; p < 0.001). Males outnumbered females in cases (60.4 vs. 39.6%) and controls (56 vs. 44%). Stratification by age group (< 30, 30 – 39, 40 – 49 and ≥ 50 years) revealed that 48.3% of cases clustered in the age group ≥ 50 years. ABO blood group analysis showed that group A was the most common among cases, while group O was the most common among controls (35.5 and 36.7%, respectively). Blood groups A (35.5 vs. 32.7; corrected p [pc] = 0.021), A+AB (46.3 vs. 41.7%; pc = 0.021) and A+B+AB (68.0 vs. 63.3%; pc = 0.007) showed significantly elevated frequencies in cases compared to controls. Logistic regression analysis estimated odds ratios (ORs) of 1.53 (95% confidence interval [CI]: 1.16 - 2.02), 1.48 (95% CI: 1.14 - 1.93) and 1.50 (95% CI: 1.17 - 1.82) for blood groups A, A+AB and A+B+AB, respectively. Blood group frequencies showed no significant differences between age groups of cases or controls. Regarding gender, male cases were marked with increased frequency of group A (39.9 vs. 28.9%) and decreased frequency of group O (25.9 vs. 41.0%) compared to female cases. Independent re-analysis of ABO blood groups in male and female cases demonstrated that group A was increased in male cases compared to male controls (39.9 vs. 33.1%; OR = 1.65; 95% CI: 1.24 - 2.21; pc = 0.006). On the contrary, no significant differences were found between females of cases and controls. Conclusions The study results indicated that blood group A may be associated with an increased risk of developing COVID-19, particularly in males.
Introduction and Aim: In medicine, the term ‘cancer’ is used to describe a group of disorders defined by uncontrolled cell growth and the ability to invade and metastasize to other organs. As a result of the body's ability to fight conventional cancer treatments, it is essential to look for alternative therapeutic avenues. Recent years have seen a rise in the application of reverse genetics techniques including the Newcastle disease virus as an oncolytic agent in tumor models of immunocompetent malignancy. In preclinical studies, recombinant NDV (rNDV-GFP) that expresses foreign genes was shown to be more effective in cancer therapy. The goal of this study was to examine the in vitro anticancer effects of GFP-expressing, genetically modified Newcastle disease virus (rClone3-GFP) strains on the JHH5 hepatocellular carcinoma cell line. Materials and Methods: To generate a recombinant NDV, the GFP gene was inserted into the genome of an NDV strain (NDVClone30) by reverse genetics technology, where it now resides in the region of the genome occupied by the F and HN genes (rNDV-GFP). Using the MTT assay, we evaluated rNDV-GFP for its oncolytic potential against JHH5 cancer cells. Cytopathic effects were analyzed using fluorescent and light microscopy. Results: We observed that 96 hours post infection, the recombinant virus was capable of inducing tumor cell death in a time-dependent way. Conclusion: Recombinant NDV strains expressing GFP, demonstrated good results in inhibiting tumor growth. Our results pave the door for the application of recombinant NDV as a viral vector for the treatment of liver cancer.
The novel SARS-CoV-2 belongs to the beta coronaviruses and causes a severe pandemic disease named as COVID-19. In late December 2019. WHO situation reports on 11 March 2020, declared that COVID-19 a pandemic due to its global spread. All Arab countries have reported COVID-19 cases. The confirmed cases of COVID-19 pandemic in Arab gulf countries were reported in the United Arab Emirates, Iraq, Bahrain, Oman, Qatar, Kuwait, and Saudi Arabia, respectively. The fatality case rates in Gulf Countries are less than 1% in Oman, UAE, Kuwait, Bahrain, and Saudi Arabia, yet it hits 7.5% in Iraq. In this manuscript, we try to interpret the pandemic statistically in gulf countries, especially in Iraq. Additionally, the distribution of COVID-19 confirmed cases based on ABO blood groups were investigated. Epidemiological analyses revealed that a decreased risk of infection was attributed to blood group O compared to non-O blood groups, whereas people with the A and A.B. blood groups showed the highest risk for COVID-19 infection. Besides, high risk for diabetes, cardiovascular disease, blood clotting, and interleukin secretion was also related to blood groups in different orders. Accordingly, patients with a specific blood group that are associate with the above diseases should be under strict medical surveillance when infected with COVID-19 to reduce complications and severity. This study provides further confirmation for the previously reported correlation between the ABO blood groups and the susceptibility to COVID-19 infection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.